WLWeiying Liu

Weiying Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weiying Liu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of Gut Mycobiome in Lung Cancer Immunotherapy: Mechanisms, Challenges and Translational Prospects

    by Xinyi Wang, Yu Sun, Min Liu, Zixuan He, Wenjiao Cao, Weiying Liu

    Role of Gut Mycobiome in Lung Cancer Immunotherapy: Mechanisms, Challenges and Translational Prospects

  • Open Access

    Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

    by Guorong Chen, Bahu Bao, Yucai Ye, Aoyan Hu, Jingzi Sun, Weiying Liu

    Background: Although the systemic immune-inflammation index (SII) has emerged as a potential prognostic marker in various cancers, its specific role in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy remains insufficiently explored. To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors (ICIs).Method: A comprehensive search was conducted across multiple databases—including PubMed, EMBASE, Cochrane and Web of Science—to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of SII for survival outcomes.Result: Ten studies involving a total of 1,547 patients were included. High systemic immune-inflammation index (SII) was significantly associated with worse overall survival (OS) (HR=1.44, 95% CI=1.21–1.70, p < 0.001; I²=3.8%) and progression-free survival (PFS) (HR=1.44, 95% CI=1.21–1.71, p < 0.001; I²=37.2%). Subgroup analysis indicated that an SII >792 was significantly associated with poorer OS and PFS.Conclusion: High SII is significantly associated with poorer OS and PFS, particularly when SII >792.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586791, identifier RD42024586791.


  • Good syndrome combined with multiple microbial pulmonary infections: case report and review of the literature

    by Yucai Ye, Juan Wang, Bahu Bao, Guorong Chen, Aoyan Hu, Jingzi Sun, Weiying Liu

    Good syndrome (GS), a rare acquired immunodeficiency disorder characterized by thymoma and hypogammaglobulinemia, predisposes individuals to recurrent infections. This study reports a case of a 37-year-old male GS with multiple pulmonary infections and reviews relevant literature. The patient, with a history of thymoma resection, experienced multiple hospitalizations due to lung infections and neutropenia. The alveolar lavage fluid was detected by macro-genomic sequencing (NGS) to detect multiple pathogens, and targeted anti-infective and immunity-enhancing treatments led to improved symptoms and normal neutrophil counts. A literature review of 98 case reports from 2000 to 2023 was conducted, summarizing the associated diseases and pathogens in GS patients. Regular immunoglobulin monitoring in thymoma patients is essential for early GS diagnosis. When empirical antimicrobial therapy fails, mNGS for pathogen detection and targeted therapy are crucial, and regular IVIG injections can reduce infection rates in GS patients.


  • Salidroside Improves Cellular Senescence in COPD by Inhibiting the JAK2/STAT3 Pathway

    by Leping Li, Wenli Fu, Juan Wang, Sha Zhang, Weiying Liu

    Background: Chronic obstructive pulmonary disease (COPD) is a respiratory illness, with cellular senescence recognized as an essential mechanism driving this chronic lung disease. Salidroside (Sal), a natural compound, is recognized for its anti-aging impacts. Therefore, this study aims to investigate the role and the underlying mechanism of Sal on airway epithelial cell senescence. Methods: In vitro experiments were performed by treating BEAS-2B cells with cigarette smoke extract (CSE), AG490 (Janus kinase 2 (JAK2) inhibitor), or Sal (40 μM, 80 μM, 160 μM). Moreover, senescence-associated β-galactosidase (SA-β-gal) staining and the manifestation of senescence-related genes were used to assess cellular senescence. The mRNA levels of cyclin-dependent kinase inhibitor 2a (p16) and cyclin-dependent kinase inhibitor 1a (p21) were evaluated. Furthermore, Western blot analysis was employed to determine the expression levels of p16, p21, Janus kinase 2 (JAK2), phosphorylated-JAK2 (p-JAK2), signal transducer and activator of transcription 3 (STAT3), and phosphorylated-STAT3 (p-STAT3). Additionally, the cytokine levels associated with the senescence-associated secretory phenotype (SASP) were evaluated utilizing corresponding enzyme-linked immunosorbent assay kits. Results: In vitro, cellular experiments demonstrated that Human bronchial epithelial cells underwent senescence in response to CSE, as evidenced by elevated expression of p16 (p < 0.05) and p21 (p < 0.05), and promotion of senescence-associated secretory phenotype (SASP), as well as up-regulation of JAK2/STAT3 signaling pathway activity. AG490 treatment significantly ameliorated CSE-induced cellular senescence, resulting in down-regulation of the JKA2/STAT3 signaling pathway, alleviation of the senescence molecules p16 (p < 0.05), p21 (p < 0.05), p-JKA2 (p < 0.01) and p-STAT3 (p < 0.05). The inhibitor decreased the secretion of SASP cytokines, and decreased the activity of SA-β-gal. Additionally, Sal reduced p16 (p < 0.01) and p21 (p < 0.05) expression, potentially reversed CSE-induced cellular senescence, and inhibited the JAK2/STAT3 signaling pathway, as well as decreased SASP secretion and SA-β-gal activity. Conclusion: Sal reduces CSE-induced BEAS-2B cellular senescence by inhibiting the JAK2/STAT3 signaling pathway, providing a novel strategy for COPD treatment.


  • Open Access

    Good syndrome combined with neutropenia and multiple microbial pulmonary infections: case report and review of the literature

    by Yucai Ye, Juan Wang, Bahu Bao, Guorong Chen, Aoyan Hu, Jingzi Sun, Weiying Liu

    Introduction Good syndrome (GS) is a rare acquired immunodeficiency disease characterized primarily by thymoma and hypogammaglobulinemia that predisposes to the risk of recurrent infections with multiple pathogens. Case representation We describe the case of a 37-year-old male GS with a history of thymoma resection who was hospitalized for multiple pulmonary infections with neutropenia and whose empirical antimicrobial therapy and promotion of granulopoiesis resulted in the resolution of the pulmonary infections and return of the neutrophil count to normal. The patient was hospitalized again for lung infection with neutropenia. Experienced antimicrobial treatment and promotion of granulocytosis were ineffective, and the alveolar lavage fluid was detected by high-throughput sequencing (NGS) to be infected with Bordetella parapertussis, Streptococcus pneumoniae, cytomegalovirus, Torque teno virus, Candida albicans, and Pneumocystis jirovecii, and the patient's neutrophil counts returned to normal after targeted anti-infective treatment and immunity-enhancing therapy. After targeted anti-infection and immunity-boosting treatment, the patient's lung infection subsided and his neutrophil count normalized. Conclusion When patients with thymoma have recurrent abnormal infections, immunologic testing should be performed to clarify whether GS is present, and anti-infective therapy should be aggressively administered.

  • Open Access

    Good syndrome combined with myelodysplastic syndrome and multiple microbial pulmonary infections: A case report and literature review

    by Yucai Ye, Juan Wang, Bahu Bao, Guorong Chen, Aoyan Hu, Jingzi Sun, Weiying Liu

    Introduction Good syndrome (GS) is a rare acquired immunodeficiency disease characterized by thymoma and hypogammaglobulinemia that predisposes to the risk of recurrent infections with multiple pathogens. Case representation We describe the case of a 37-year-old male with GS who had a history of thymoma resection combined with myelodysplastic syndrome and was hospitalized multiple times for infections. The patient was admitted to our hospital with reoccurring fever, empirical antimicrobial therapy was ineffective, and Streptococcus pneumoniae, cytomegalovirus, cytomegalovirus, fine cyclic virus, Candida albicans, and Pneumocystis japonicus infections were identified by high-throughput sequencing technology (NGS) testing of alveolar lavage fluid, and the patient's symptoms resolved and immunity was improved with targeted anti-infective therapy. Conclusion When patients with thymoma have recurrent abnormal infections, immunologic testing should be performed to clarify whether GS is present, and anti-infective therapy should be aggressively administered.

  • Effects of CPAP and Mandibular Advancement Devices on depressive symptoms in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials

    by Wenli Fu, Leping Li, Sha Zhang, Shengfei Liu, Weiying Liu

    Purpose Studies show that patients with obstructive sleep apnea (OSA) are more likely than the general population to have psychological disorders such as depression. However, it is less clear how OSA treatment affects this association. This meta-analysis aimed to assess whether or not continuous positive airway pressure (CPAP) and mandibular advancement devices (MADs) reduce depression symptoms in patients with OSA. Methods We searched Pubmed, Embase, Web of Science, and Cochrane Library from creating the databases until November 2022. Our analysis included RCTs that examined CPAP and MAD treatment effectiveness for depression in patients with OSA. Results We identified 17 CPAP studies comprising 1,931 patients for inclusion in the meta-analysis. The results of the meta-analysis using a fixed effects model found that CPAP improved depressed mood in patients with OSA relative to controls (SMD = 0.27;95% CI:0.18,0.36), with small heterogeneity among trials (I2 = 8.1% < 50%, P = 0.359). We performed subgroup analyses on three factors: the length of trial follow-up, patient adherence data, and depression assessment scales. The meta-analysis also identified six MAD studies involving 315 patients. According to this analysis, there was no heterogeneity between studies (I2 = 0%, P = 0.748). MADs did not significantly improve depression symptoms compared to controls, indicating a combined effect of SMD = 0.07 (95% CI: − 0.15,0.29), P > 0.05. Conclusion The present findings confirm that CPAP may improve depressive symptoms in patients with OSA. However, the review results suggest that MADs have no significant effect on depressive symptoms in patients with OSA, a finding that is different from the results of previous meta-analyses.


  • Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review

    by Chen Wu, Weiying Liu, Jiayuan Pu, Tao Feng, Yingxuan Chang, Xin Wang, Xuejie Liang, Jinjun Kai

    Checkpoint inhibitor pneumonitis (CIP) is a relatively rare adverse event and a potential cause of death in patients treated with immune checkpoint inhibitors (ICIs). Because the symptoms and signs... Plain language summary We report a patient with advanced lung cancer who experienced shortness of breath induced by immunotherapy. The levels of nitric oxide from the exhaled breath in this case sh...


  • Regulatory mechanism of downregulation of SOD1 expression on cardiomyocyte function

    by Na Dong, Wei-Ying Liu

    Background Many diseases are clinically related to oxidative stress. Obstructive sleep apnea (OSA) is a common disease with oxidative stress in clinical practice, which is mostly associated with cardio-cerebrovascular diseases. It has been shown that the level of oxidative stress increases and the level of antioxidant copper zinc superoxide dismutase (SOD1) decreases in intermittent hypoxia (IH). SOD1 is one of the key antioxidant enzymes in organisms, and it can also be used as a signal transmission controller. Its abnormal expression further affects organ functions, but the specific mechanism is not yet fully clear. Methods We downregulated the SOD1 gene in H9C2 cell line, using high-throughput RNA sequencing (RNA-seq) to find differentially expressed genes (DEGs) related to cardiomyocyte function by using GO and KEGG databases to annotate, enrich and analyze the metabolic pathways of DEGs. Results Through the analysis of these functional gene changes, we can understand the regulation of SOD1 downregulation on cardiomyocyte function. The results found 213 DEGs, of which 135 genes were upregulated and 78 genes were downregulated. The upregulated DEGs were mainly enriched in biological processes such as transcriptional regulation and metabolism. The expression levels of EGR1 and NR1D1 exceeded 1 in the samples. EGR1 was reported to be involved in oxidative stress and cardiac hypertrophy, and NR1D1 played an important regulatory role in regulating inflammatory responses and reducing ROS production. The biological processes involved in downregulated DEGs mainly involve metabolism and redox processes. Among them, SCD1 and CCL2 genes were highly expressed among the genes involved in the redox process involved in SOD1. SCD1 is an important player in the regulation of cardiometabolic processes; downregulation of CCL2 reduces atherosclerosis. We found that the TNF signaling pathway, NOD-like receptor signaling pathway, and chemokine signaling pathway, which were enriched in KEGG analysis, were all associated with inflammation, and the CXCL1 and CCL7 genes are all related to inflammation. Conclusion The gene and signaling pathways involved in oxidative stress and inflammatory response process regulated by SOD1 were demonstrated. SOD1 may affect the function of the heart by affecting myocardial contraction, inflammation, lipid metabolism, and other pathways. It is inferred that they may also play a role in the process of OSA-related myocardial injury, which is worthy of attention and further study.